European Archives - Page 634 of 1230 - European Medical Journal

The Alternative: Herbal Medicine

This week, Jonathan continues his series on alternative medicine by taking us back in time to the roots of medicine through herbal remedies.

Factor XI Inhibition: The Holy Grail of Haemostasis-Sparing Anticoagulation

Ajay Kakkar opened this virtual meeting by discussing the history of the treatment and prevention of thrombosis…

EMJ 6.4 2021

Email subject line: Homozygous familial hypercholesterolaemia and biomarkers for COVID-19 in EMJ 6.4Introduction…

Evra (Norelgestromin and Ethinyl Oestradiol) and Contraceptive Options Available to Females Today

Increased contraceptive choice is a pivotal shift in modern contraception that has improved the autonomy of females and may help to better match contraception to their individual and cultural identities.

Neurofibromatosis Type 1: Burden of Disease in Patients with Plexiform Neurofibromas

NF1 is an autosomal dominant disorder, arising from a mutation in the gene that encodes neurofibromin. It is a tumour-predisposing…

Management and Multi-specialty Approach in the Evolving Treatment Landscape of Neurofibromatosis Type 1 Plexiform Neurofibromas

Neurofibromatosis Type 1 (NF1) is a rare disease, occurring in approximately 1 in 3,000 people. Among the numerous manifestations…

Aficamten: A New Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

REDWOOD-HCM was a multicentre, randomised, placebo-controlled, double-blind, dose-finding clinical trial of aficamten in patients with symptomatic oHCM on background medical therapy.

Automated Echocardiography Analysis: Expanding Access and Saving Time

December marks the launch of Us2.ai’s automated cardiac analysis platform1 as a cloud-based service on the EchoNous Kosmos device…

Identifying Common Biomarkers Between COVID-19 and Commonly Associated Comorbidities

The recent COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, since its…

Current Therapy for Homozygous Familial Hypercholesterolaemia

Homozygous familial hypercholesterolaemia (HoFH) is a rare and aggressive disorder, resulting from the inheritance of mutations in the two alleles of genes regulating the low-density lipoprotein receptor (LDL-R) function.